Companies /Healthcare

Agilent Technologies Inc

NYSE: A Diagnostics & Research
$157.88
â–² $2.80 (+1.80%) today
Markets open · 12:51pm ET

Q2 2026 Earnings

Reported May 27, 2026, 4:06pm ET · SEC source
$1.49
Beat +5.80%
EPS · est. $1.41
$1.8B
Beat +2.03%
Revenue · est. $1.8B
−0.8%
Trailing market
A vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%0+6%+12%May 27May 28report 4:06pm ETearnings+0.6%+11.0%
−6%0+6%+12%May 27May 28earnings+0.6%+11.0%
A +11.0%S&P 500 +0.6%
−6%0+6%+12%May 27May 28report 4:06pm ETearnings+0.9%+11.0%
−6%0+6%+12%May 27May 28earnings+0.9%+11.0%
A +11.0%NASDAQ +0.9%
−12%−6%0+6%May 26Jun 4report 4:06pm ETearnings+0.5%+5.6%
−12%−6%0+6%May 26Jun 4earnings+0.5%+5.6%
A +5.6%S&P 500 +0.5%
−12%−6%0+6%May 26Jun 4report 4:06pm ETearnings+1.0%+5.6%
−12%−6%0+6%May 26Jun 4earnings+1.0%+5.6%
A +5.6%NASDAQ +1.0%
+16.87%
Day of report
+0.11%
Next session
+2.21%
One week
−1.88%
30 days

S&P 500 over the same 30 days: −1.04%.

Did A Beat Earnings? Q2 2026 Results

Agilent Technologies posted a convincing second quarter of fiscal 2026, with revenue of $1.83 billion rising 10.0% year-over-year and non-GAAP EPS of $1.49 beating the $1.41 consensus estimate by 5.80%, as broad-based segment strength and margin discipline drove results ahead of expectations across the board. The Applied Markets Group led reported growth at 14%, while the Life Sciences and Diagnostics Markets Group added 12%, and the company's ongoing Ignite Operating System initiative helped expand non-GAAP operating margin by 130 basis points year-over-year to 26.4%, underscoring that the operational transformation is translating into tangible financial gains. Revenue came in 2.03% above the $1.80 billion consensus, adding to the quarter's clean beat. With analysts at multiple firms maintaining bullish views on the stock ahead of the print, the results appear to validate that confidence. Looking ahead, Agilent raised its full-year fiscal 2026 non-GAAP EPS guidance to $6.00 to $6.10 and revenue to $7.39 billion to $7.49 billion, reflecting management's growing conviction in sustained demand momentum.

Key Takeaways
  • Broad-based strength across key end markets
  • Exceptional operational execution and strong margin performance
  • Increasing impact of Ignite Operating System across the organization
  • Replacement-cycle momentum
  • Healthy underlying demand
  • Currency tailwinds contributing approximately 4 percentage points to reported growth
  • Non-GAAP operating margin expanded 130 basis points YoY to 26.4%

“It was an excellent second quarter for Agilent, with broad-based strength across key end markets, exceptional operational execution and strong margin performance.”

Agilent Technologies CEO, on the earnings call

Forward Guidance & Outlook

Agilent raised its fiscal year 2026 guidance. Revenue is now expected in the range of $7.39 billion to $7.49 billion, representing reported growth of 6.3% to 7.8% and core growth of 4.5% to 6.0%, an increase of 30 basis points at midpoint. Non-GAAP operating margin expansion at the midpoint of core revenue growth guidance is now expected to be 85 basis points, up 10 basis points. Non-GAAP EPS is now expected in the range of $6.00 to $6.10, an increase of $0.08 at midpoint. For fiscal Q3 2026, revenue is expected in the range of $1.83 billion to $1.85 billion (growth of 5.0% to 6.5% reported, 4.4% to 5.9% core) with non-GAAP EPS of $1.48 to $1.50.

A YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$600.0M$1.2B$1.8B$1.7B$1.8BRevenue$866.0M$990.0MGross Profit$300.0M$399.0MOperating Income$215.0M$339.0MNet Income
$0$600.0M$1.2B$1.8BRevenueGross ProfitOperating IncomeNet Income

A Revenue by Segment

Agilent CrossLab Group$759.0M+6.0%
Life Sciences and Diagnostics Markets Group$732.0M+12.0%
Applied Markets Group$344.0M+14.0%

Figures from SEC filings and company reports. Not investment advice.